Display options
Cite
Alhakamy NA, Badr-Eldin SM, Alharbi WS, et al. Development of an Icariin-Loaded Bilosome-Melittin Formulation with Improved Anticancer Activity against Cancerous Pancreatic Cells. Pharmaceuticals (Basel). 2021;14(12)doi: 10.3390/ph14121309.
Alhakamy, N. A., Badr-Eldin, S. M., Alharbi, W. S., Alfaleh, M. A., Al-Hejaili, O. D., Aldawsari, H. M., Eid, B. G., Bakhaidar, R., Drago, F., Caraci, F., & Caruso, G. (2021). Development of an Icariin-Loaded Bilosome-Melittin Formulation with Improved Anticancer Activity against Cancerous Pancreatic Cells. Pharmaceuticals (Basel, Switzerland), 14(12), . https://doi.org/10.3390/ph14121309
Alhakamy, Nabil A, et al. "Development of an Icariin-Loaded Bilosome-Melittin Formulation with Improved Anticancer Activity against Cancerous Pancreatic Cells." Pharmaceuticals (Basel, Switzerland) vol. 14,12 (2021). doi: https://doi.org/10.3390/ph14121309
Alhakamy NA, Badr-Eldin SM, Alharbi WS, Alfaleh MA, Al-Hejaili OD, Aldawsari HM, Eid BG, Bakhaidar R, Drago F, Caraci F, Caruso G. Development of an Icariin-Loaded Bilosome-Melittin Formulation with Improved Anticancer Activity against Cancerous Pancreatic Cells. Pharmaceuticals (Basel). 2021 Dec 15;14(12). doi: 10.3390/ph14121309. PMID: 34959710; PMCID: PMC8703505.
Copy Download .nbib Format: NLM
Share it on

Pharmaceuticals (Basel). 2021 Dec 15;14(12). doi: 10.3390/ph14121309.

Development of an Icariin-Loaded Bilosome-Melittin Formulation with Improved Anticancer Activity against Cancerous Pancreatic Cells.

Pharmaceuticals (Basel, Switzerland)

Nabil A Alhakamy, Shaimaa M Badr-Eldin, Waleed S Alharbi, Mohamed A Alfaleh, Omar D Al-Hejaili, Hibah M Aldawsari, Basma G Eid, Rana Bakhaidar, Filippo Drago, Filippo Caraci, Giuseppe Caruso

Affiliations

  1. Department of Pharmaceutics, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
  2. Advanced Drug Delivery Research Group, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
  3. Center of Excellence for Drug Research and Pharmaceutical Industries, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
  4. Mohamed Saeed Tamer Chair for Pharmaceutical Industries, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
  5. Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt.
  6. Vaccines and Immunotherapy Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
  7. Department of Pharmacology and Toxicology, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia.
  8. Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.
  9. Department of Drug and Health Sciences, University of Catania, 95125 Catania, Italy.
  10. Oasi Research Institute-IRCCS, 94018 Troina, Italy.

PMID: 34959710 PMCID: PMC8703505 DOI: 10.3390/ph14121309

Abstract

Pancreatic cancer currently represents a severe issue for the entire world. Therefore, much effort has been made to develop an effective treatment against it. Emerging evidence has shown that icariin, a flavonoid glycoside, is an effective anti-pancreatic cancer drug. Melittin, as a natural active biomolecule, has also shown to possess anticancer activities. In the present study, with the aim to increase its effectiveness against cancerous cells, icariin-loaded bilosome-melittin (ICA-BM) was developed. For the selection of an optimized ICA-BM, an experimental design was implemented, which provided an optimized formulation with a particle size equal to 158.4 nm. After estimation of the release pattern, the anti-pancreatic cancer efficacy of this new formulation was evaluated. The MTT assay was employed for the determination of half maximal inhibitory concentration (IC

Keywords: apoptosis; bilosomes; icariin; melittin; pancreatic cancer

References

  1. Polymers (Basel). 2021 Mar 13;13(6): - PubMed
  2. Int Immunopharmacol. 2011 Jul;11(7):890-8 - PubMed
  3. J Sep Sci. 2007 Jun;30(9):1307-12 - PubMed
  4. Ther Clin Risk Manag. 2006 Dec;2(4):435-45 - PubMed
  5. Int J Mol Sci. 2018 Nov 29;19(12): - PubMed
  6. Cell Death Dis. 2018 Sep 20;9(10):940 - PubMed
  7. Biochem Pharmacol. 2015 Aug 1;96(3):278-87 - PubMed
  8. Front Bioeng Biotechnol. 2021 Feb 26;9:615920 - PubMed
  9. World J Oncol. 2019 Feb;10(1):10-27 - PubMed
  10. Curr Pharm Des. 2017;23(11):1575-1588 - PubMed
  11. Int J Pharm. 2015 May 15;485(1-2):329-40 - PubMed
  12. Drug Discov Today. 2016 Jun;21(6):888-99 - PubMed
  13. Cytotechnology. 2019 Dec;71(6):1109-1120 - PubMed
  14. Braz J Med Biol Res. 2018 Aug 06;51(10):e7151 - PubMed
  15. Int J Oncol. 2015 Jan;46(1):78-90 - PubMed
  16. Biomolecules. 2020 Feb 06;10(2): - PubMed
  17. NPJ Precis Oncol. 2020 Sep 1;4(1):24 - PubMed
  18. Carcinogenesis. 2013 Dec;34(12):2870-9 - PubMed
  19. Sci Rep. 2016 Feb 19;6:21145 - PubMed
  20. Cancer Lett. 2017 Jul 28;399:1-9 - PubMed
  21. Mol Cell Biochem. 2017 Jan;425(1-2):85-93 - PubMed
  22. Oncogene. 2013 Mar 28;32(13):1616-25 - PubMed
  23. Cell Mol Biol (Noisy-le-grand). 2016 Apr 30;62(4):123-9 - PubMed
  24. Mol Med Rep. 2015 Nov;12(5):6815-20 - PubMed
  25. Hum Reprod. 2018 Oct 1;33(10):1817-1828 - PubMed
  26. Biomed Pharmacother. 2019 Oct;118:109275 - PubMed
  27. Drug Deliv. 2018 Nov;25(1):1340-1349 - PubMed
  28. Cancer Cell Int. 2013 Feb 09;13(1):12 - PubMed
  29. Curr Protein Pept Sci. 2019;20(3):240-250 - PubMed
  30. Antioxidants (Basel). 2021 Jul 05;10(7): - PubMed
  31. World J Gastroenterol. 2013 Feb 14;19(6):813-28 - PubMed
  32. Cancers (Basel). 2020 Jan 01;12(1): - PubMed
  33. Cancer Cell Int. 2016 May 26;16:39 - PubMed
  34. PLoS One. 2017 Jun 7;12(6):e0178930 - PubMed
  35. AAPS PharmSciTech. 2014 Aug;15(4):822-33 - PubMed
  36. Int J Mol Sci. 2020 Jan 25;21(3): - PubMed
  37. Front Pharmacol. 2016 Jun 29;7:191 - PubMed
  38. Biomed Pharmacother. 2018 Mar;99:810-816 - PubMed
  39. Materials (Basel). 2021 Jun 04;14(11): - PubMed
  40. Int J Nanomedicine. 2018 Aug 20;13:4727-4745 - PubMed
  41. Int J Nanomedicine. 2020 Dec 08;15:9783-9798 - PubMed
  42. Environ Toxicol Pharmacol. 2017 Sep;54:7-13 - PubMed
  43. Molecules. 2019 Jun 29;24(13): - PubMed
  44. J Photochem Photobiol B. 2017 Jan;166:301-310 - PubMed
  45. Pharmaceutics. 2021 Apr 29;13(5): - PubMed
  46. Sci Rep. 2019 Aug 30;9(1):12613 - PubMed
  47. Eur J Pharm Biopharm. 2021 Jun;163:223-239 - PubMed
  48. CA Cancer J Clin. 2018 Nov;68(6):394-424 - PubMed
  49. PLoS One. 2014 Oct 16;9(10):e110003 - PubMed
  50. J Huazhong Univ Sci Technolog Med Sci. 2014 Aug;34(4):497-503 - PubMed
  51. Pharmaceutics. 2020 Apr 11;12(4): - PubMed
  52. Pharmaceutics. 2021 Nov 01;13(11): - PubMed
  53. Adv Drug Deliv Rev. 2001 Oct 1;50 Suppl 1:S127-47 - PubMed

Publication Types

Grant support